Conversely, studies with blockade of the CCL5 receptor—CCR5—using the FDA-approved antagonist Maraviroc, or employing neuron-specific CCR5 knockout mice, further supported neuroprotective effects in both stroke and controlled cortical impact (CCI)-induced TBI models [24]. The gene discussed is CCR5; the disease is stroke disorder.